Beam Therapeutics (BEAM) said Monday it has priced an underwritten offering of 16.2 million shares at $28.48 per share, and pre-funded warrants to purchase 1.4 million shares at $28.47 per pre-funded warrant.

Gross proceeds from the offering, expected to close Tuesday, are anticipated to be about $500.0 million, the company said.

Beam said intends to use net proceeds from the offering for technology advancement, research and development, and other general corporate purposes.